Amgen received approval from the FDA for the expansion of KYPROLIS (carfilzomib) to include its use in combination with Janssen’s DARZALEX (daratumumab) plus dexamethasone (DKd) in two dosing regimens — once weekly and twice weekly — for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy. “This expanded approval for KYPROLIS demonstrates a leap forward in the treatment paradigm for this complex disease b...